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Background. Hepatitis C virus (HCV) is an underappreciated cause of pediatric liver disease, most frequently
acquired by vertical transmission (VT). Current guidelines that include the option of screening infants for HCV
RNA at 1–2 months are based on data prior to current real-time polymerase chain reaction (PCR)-based testing.
Previous studies have demonstrated VT rates of 4%–15% and an association with high maternal viral load. We eval-
uated HCV RNA in infants with HCV VT and assessed maternal risk factors in a prospective cohort in Cairo, Egypt.
Methods. Pregnant women were screened for HCV from December 2012 to March 2014. For those with HCV
viremia, their infants were tested at 12 months for HCV RNA using real-time PCR. Maternal risk factors assessed for
HCV VT association included HCV RNA levels, mode of delivery, and maternal IL28B genotype.
Results. Of 2514 women screened, a total of 54 women were viremic (2.1%) and delivered 56 infants. Of those,
51 infants of 49 women were tested at 12 months of age. Only 7 infants were viremic, with an HCV VT rate of 14.3%
(7 of 49). Median HCV RNA in the infants was 2100 IU/mL. None of the maternal risk factors analyzed were as-
sociated with transmission.
Conclusions. In Egypt where HCV is highly endemic, we observed an overall 12-month HCV VT rate of 14.3%.
Further studies should focus on better identification of pregnant women more likely to vertically transmit HCV and
earlier testing of infants to identify those likely to develop chronicity.
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Hepatitis C virus (HCV) is a well known cause of adult
liver morbidity and mortality, but its burden on chil-
dren is often overlooked [1, 2]. Estimates of the pediatric
burden of HCV in the United States include 25 000–
50 000 existing cases and projected costs of $168–
$404 million in the current decade before the approval
of new and very expensive antiviral agents [3]. These
figures are dwarfed by estimates from Egypt, where
the overall HCV seroprevalence is almost 15 times high-
er than in the United States [4–9]. Although many chil-
dren in the United States acquired HCV from infected
blood or blood products prior to effective screening, the
leading route of pediatric acquisition of HCV in most
parts of the world is now vertical transmission (VT)
[4, 10].
Previous studies of HCV VT demonstrated that ap-
proximately 4%–15% of infants become infected, but
approximately half of those will spontaneously resolve
their infection in the first 2 years of life [11–13].
These studies also described many infants with either
episodic viremia or viremia that became detectable
after several months of life. Hepatitis C virus RNA was
detected in these HCV VT studies using older reverse
transcriptase-polymerase chain reaction (RT-PCR) as-
says that yielded a qualitative result (positive or negative)
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with less sensitivity. One study used a nested RT-PCR tech-
nique to increase the sensitivity of the assay [12]. Currently
used methods for HCV RNA detection use real-time PCR tech-
nology, which offers increased sensitivity for low quantities of
HCV RNA (25 IU/mL lower limit of detection) coupled with
a broad dynamic range (up to 108 IU/mL) for quantitation
when compared with older RT-PCR methods (∼103 IU/mL)
[14, 15]. Despite these meaningful improvements, there have
been no studies that examined the performance of the current
real-time assays in diagnosing HCV VT. Given that this is the
leading route of pediatric acquisition of HCV and the assay is
not currently being used for this purpose, one of our main
study objectives was to fill this knowledge gap.
Prior studies of HCV VT have also examined whether certain
maternal risk factors are associated with a higher rate of trans-
mission [16]. Maternal HCV viral load has been implicated in
several studies, but there is no defined level that is predictive of
transmission [12, 17].Mode of delivery has been examined, and
Caesarean section has not been found protective of transmis-
sion [17–19]. Coinfection with human immunodeficiency
virus (HIV) was demonstrated to increase the risk of HCV
VT, but those studies were all done before highly active antire-
troviral therapy [17, 20–22].A recent study done in women with
well controlled HIV demonstrated an HCV VT rate that was
comparable to those with HCV monoinfection [23]. Given the
association of IL28B rs12979860 genotype with a significantly
enhanced rate of response to interferon-based therapy as well
as with spontaneous resolution of HCV, 1 study investigated
its association with HCV VT and found none [24–26].
Here, we describe the results of a 12-month follow up of in-
fants born to HCV-infected pregnant women identified as part
of a universal screening program we implemented in Cairo,
Egypt [27]. We tested for the HCV RNA levels in their infants
at 12 months of age and analyzed maternal risks for possible
association with HCV VT.
METHODS
Detailed study procedures were described previously [27]. In
brief, all pregnant women attending Cairo University Faculty
of Medicine Obstetrics and Gynecology antenatal clinic were
approached for HCV screening. After obtaining their informed
consent, screening for HCV was performed on all women, and
HCV RNA testing was performed on those who tested positive
for antibodies to HCV. Prenatal care was conducted as per the
usual standards. After delivery, the HCV-infected women were
observed every 3 months after delivery for repeat testing and
follow-up antenatal care. Infants were observed at 12 months
of age for HCV RNA testing as part of the study. The study
was independently approved by the Cairo University, University
of North Carolina at Chapel Hill, and the University of Mary-
land School of Medicine institutional review boards. Each
pregnant woman signed a written informed consent form
after all her questions were addressed, and for illiterate women,
a literate companion attended the consenting process and co-
signed the informed consent after all of their questions were
addressed.
Laboratory Testing
Maternal blood samples were tested for HCV antibodies using
a fully automated electrochemiluminescence immunoassay
(Elecsys Anti-HCV immunoassay on the Cobas; Roche). Positive
maternal samples and all infant samples were tested for quanti-
tative HCV RNA using the Roche LightCycler 2.0 (real-time
PCR) as described elsewhere [28]. Maternal IL28B assessment
was performed using the TheLightMix IL28B allelic discrimina-
tion kit from Roche Diagnostics (Mannheim, Germany) for the
detection of the human IL28B C/T polymorphism (rs12979860)
in human nucleic acid extracts. This LightMix Kit was tested on
the LightCycler 2.0 Instrument with the LightCycler FastStart
DNA HybProbeMastermix.
Data Analysis
The prevalence of anti-HCV and HCV RNA was calculated
using Microsoft Excel. The associations between maternal risk
factors and VT were assessed and described, and given the small
number of infected infants, nonparametric tests were used to
compare between them: Fisher’s Exact test was used for categor-
ical variables, and the Mann-Whitney U test was used for con-
tinuous variables. Analyses were performed using the SPSS
statistical software version 22.0 (IBM SPSS Statistics for Win-
dows, Version 22.0; Armonk, NY: IBM Corp).
RESULTS
FromDecember 2012 throughMarch 2014, a total of 2514 preg-
nant women were screened at Cairo University. Of those, 98
(3.9%) were anti-HCV seropositive and 54 (2.1%) also were
positive for HCV RNA. Based on previous published studies
demonstrating VT only in women with viremia, we only per-
formed follow-up studies on infants born to those women
with viremia.
Fifty-six infants were born to the 54 viremic women, all of
whom were tested for HCV viremia. There was 1 stillbirth
and 2 infants who died at several hours of life (1 had multiple
congenital anomalies and 1 had severe obstructive uropathy).
Two infants have not yet completed 12 months of age and
have not been tested yet. This left 51 infants (2 sets of twins)
born to 49 mothers who were evaluated.
Hepatitis C Virus Vertical Transmission Rate
Of the 51 infants born to 49 mothers, 7 of 49 infants (14.3%)
were HCV RNA-positive with real-time PCR testing. Results
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are summarized in Table 1. Both sets of twins were negative for
HCV RNA.
Viral IU/mL copies ranged from 704 to 40 800 (mean = 8643,
standard deviation = 14 626). Median HCV RNA in the infants
was 2100, and 5 of the HCV RNA-positive infants had viral
quantities below 2500 IU/mL.
Analysis of Maternal Factors
We next analyzed maternal risk factors that have been reported
to be associated with HCV VT in prior studies. Results are sum-
marized in Table 1. Of the transmitting mothers, 2 had sponta-
neous vaginal deliveries and 5 underwent Cesarean section. All
but 2 of the 7 women had prior Cesarean deliveries. Among the
nontransmitting mothers, 21 had spontaneous vaginal deliver-
ies and 21 had Cesarean sections (8 were first-time surgical de-
liveries, whereas 13 were repeat). There was no association with
mode of delivery and HCV VT (P = 0.42).
We examined HCV RNA levels between transmitting moth-
ers and nontransmitting mothers. Results are summarized in
Table 1. Mean HCV RNA levels in transmitting mothers was
145 612 (median, 85 400) vs 446 093 IU/mL (median, 99 750)
in the nontransmitting mothers. There was no association
with HCV RNA and HCV VT in our cohort (P = 0.64). Based
on the distribution represented in Figure 1, one can see that
there was no correlation with HCV RNA levels and transmis-
sion, and there was no cutoff that could be established below
which VT did not occur.
We also examined the potential role of maternal IL28B geno-
type on HCV VT. When compared with the “TT” or “CT” poly-
morphism, the “CC” genetic polymorphism has been associated
with significantly higher rates of spontaneous clearance and re-
sponse to interferon-based therapy [24, 26]. Results are summa-
rized in Table 1. Among the 7 mothers that transmitted HCV to
their infants, 5 (71%) had the favorable CC genotype, 1 (14%)
had the CT genotype, and 1 (14%) had TT. Among the nontrans-
mitters, 21 (50%) were CC, 14 (33%) were CT, 5 (12%) were TT,
and 2 (5%) refused to be tested. There was no association between
IL28B genotype and HCV VT in our study (P = 0.56).
DISCUSSION
We conducted follow-up testing of infants born to Egyptian
mothers identified with HCV as part of a universal screening
program we implemented. We identified 7 infants with HCV
VT using real-time PCR testing at 12 months of age for an es-
timated transmission rate of 14.3%. To put these numbers in
additional perspective, one of the previous studies identified 9
infants with HCV VT born to 192 women with HCV RNA after
screening more than 75 000 women over a period of 4 years at 2
Figure 1. Distribution of maternal hepatitis C virus (HCV) RNA levels
and VT. This figure shows the HCV RNA levels of mothers who did, and
did not, vertically transmit HCV to their infants. Logarithmic values are pre-
sented on the y-axis and the 2 groups of mothers are plotted on the x-axis.
HCV RNA distributions are presented using a “box and whisker” plot. The
lower and upper borders of each box encompass the interquartile range
(IQR), the horizontal line inside the box represents the median, the vertical
lines from the ends of each box extend to the extreme data points, and the
open circle is an outlier value.
Table 1. Summary of Maternal Risk Factors and Their Associa-







No. of HCV RNA-
positive mothers
n = 42a n = 7
Infant HCV RNA
Median (range) N/A 2100 IU/mL
(704–40 800)
N/A
Median log N/A 3.32 N/A
Maternal Age 32 yrs (±5.2) 30.7 yrs (±5.3) 0.54
Mode of Delivery
Cesarean section 21 5 0.42
NSVD 21 2
IL28b Genotype
CC 21 (50%) 5 (71%) 0.56
CT 14 (33%) 1 (14%)
TT 5 (12%) 1 (14%)
Refused 2 (5%) 0 (0%)
Maternal HCV RNA





Median 99 750 85 400 0.64
Median log 4.99 4.93 0.62
Abbreviations: HCV, hepatitis C virus; N/A, not applicable; NSVD, normal
spontaneous vaginal delivery; VT, vertical transmission.
a Forty-four HCV RNA-negative infants born to 42 HCV RNA-positive mothers,
and 7 positive infants born to 7 positive mothers.
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sites in the United States [12]. A more recent study of HIV/
HCV coinfected women identified 4 infants born to 47 women
identified from 6 countries from 2002 to 2009 [23]. Given the
high local seroprevalence in Egypt, our patient cohort is
amongst the largest described with HCV VT.
Our findings are significant for several reasons. We conduct-
ed our follow-up studies using current real-time PCR assays.
The prior large studies that looked at HCV VT used older assays
that were less sensitive [11–13].Those same studies demonstrat-
ed that some infants had episodic viremia at various time points
in their first year of life. Real-time PCR-based testing for HCV
allows for a broad dynamic range with excellent sensitivity
down to 25 IU/mL [14]. The median HCV RNA of the infants
we tested was 2100 IU/mL. It is possible that these infants may
have tested negative with the prior assays. Current recommenda-
tions by the American Academy of Pediatrics Committee on In-
fectious Diseases (the Red Book) are that infants vertically
exposed to HCV can be tested using molecular test between 1
and 2 months, or they can be tested with an antibody test after
18 months of age [29]. This recommendation is based on studies
using the older PCR assays. As we stated before, the newer real-
time PCR assays have never been studied in this population. It is
entirely possible that several of the infants testing negative were
positive at some point earlier in life. It is also possible that some
of the infants testing positive were previously positive at a much
higher level, and some may be on their way to spontaneous res-
olution. It is well known that infants can spontaneously resolve
their viremia well into the 2nd year of life. It is also possible that
these infants may experience a steady climb in their HCV RNA
as chronic infection is established. What our results really indi-
cate is the need for a systematic study of infants vertically exposed
to HCV to determine when is the best time to use real-time PCR
testing to accurately declare them infected or uninfected.
Our findings also reinforce the lack of a single maternal risk
factor that is highly associated with HCV VT. Our analysis re-
vealed that HCV RNA, mode of delivery, or maternal IL28B sta-
tus were not associated with HCV VT. Older studies have
suggested that high HCV RNA levels were associated with
transmission, but we observed HCV VT even when maternal
viral RNA levels were below 20 000 IU/mL [12, 17, 30, 31]. Be-
cause viral RNA levels do not correlate and because mode of de-
livery or IL28B does not influence VT, these observations seem
to support one of our fundamental hypotheses about HCV VT,
which is that it is most likely an in utero event that is due to a
combination of unique viral and nonimmune-mediated host
cellular factors. The presence of VT at low maternal RNA levels
in our study does not support conclusions from prior studies
that an overwhelming perinatal HCV exposure was responsible
for infection of infants born to HCV-infected mothers with
high viral loads. It may be that certain strains are better suited
to cross the placenta but are less well suited to persist in the in-
fant, where only half of infants progress to chronic infection.
Previous studies examining changes in maternal immune re-
sponses during and after pregnancy coupled with innate immune
responses within the placenta and adaptive immunity in the chil-
dren help to define the many layers of protection against HCV
VT [32–34]. Again, these results suggest that ongoing detailed
studies examining fundamental aspects of HCV VT are required.
Our findings are subject to some limitations. We acknowl-
edge that our transmission rate is based on 1 follow-up test at
12 months and that we do not have liver function testing or
HCV antibody results. This was based on resource limitations
for testing at earlier time points. It is possible that further fol-
low-up up to 2 years or longer would result in spontaneous
clearance of some of these infections, as was observed in prior
studies done by our group [13, 34]. We are in the process of
planning a larger, more in depth study looking at the predictive
value of testing at several time points to determine which one is
optimal for outcome prediction. We made every effort to reduce
the risk of contamination when processing samples, but it is
possible that some of our low levels of RNA may be due to con-
tamination, although we did not find such evidence in repeated
maternal samples tested by the same laboratory. We also only
studied patients at 1 site in Cairo, Egypt. Although we did not
perform genotype testing on these patients, genotype 4 is seen
almost exclusively in that region [35, 36]. Previous studies have
shown that VT rates from Egypt mirror those observed in the
United States and European cohorts [13]. We do allow that
there may be inherent differences between the genotypes with
respect to VT that are not yet fully appreciated. We did not
actively screen pregnant women for HIV coinfection because
Egypt is categorized by UNAIDS as having very low HIV sero-
prevalence (http://www.unaids.org/en/regionscountries/coun
tries/egypt/). Although this cohort is relatively large for an
HCV VT study, the number of infected children was small,
and it is possible that the small sample size is a reason for the
lack of significant association with maternal risk factors. We are
continuing to screen, enroll, and observe women and their in-
fants at this site, and we plan to retest the same infants at 2 years
of life. We look forward to reporting our findings for a much
larger cohort in the future.
CONCLUSIONS
We observed a high rate of HCV VT in our cohort when using
real-time PCR for follow-up testing. Our findings suggest that
there is the potential for generating a validated algorithm
using real-time PCR to accurately segregate infected from unin-
fected infants. Larger studies should be performed with this goal
in mind.
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